Racial/ethnic differences in hepatic steatosis in a population-based cohort of post-menopausal women: The Michigan Study of Women's Health Across the Nation

Diabetic Medicine

Volumn 30, Issue 12, 2013, Pages 1433-1441

  Kim, C ^a   Harlow, S D ^a   Karvonen Gutierrez, C A ^a   Randolph, J F ^a   Helmuth, M ^a   Kong, S ^a   Nan, B ^a   Carlos, R ^b  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FOLLITROPIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; SEX HORMONE BINDING GLOBULIN; SIBUTRAMINE; SULFONYLUREA; TESTOSTERONE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ADULT; AFRICAN AMERICAN; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG USE; ESTROGEN THERAPY; ETHNIC DIFFERENCE; FATTY LIVER; FEMALE; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; RACE DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AFRICAN AMERICANS; BLOOD PRESSURE; CHOLESTEROL, LDL; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FATTY LIVER; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; MICHIGAN; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; PREVALENCE; SEX HORMONE-BINDING GLOBULIN; TRIGLYCERIDES; UNITED STATES; WOMEN'S HEALTH;

EID: 84887625762     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12225     Document Type: Article

References (34)

1. Utzschneider K, Kahn S. The role of insulin resistance in non-alcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91: 4753-4761.
2. Sung K, Jeong W, Wild S, Byrne C. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care 2012; 35: 717-722.
3. Peter A, Kantartzis K, Machann J, Shick F, Staiger H, Machicao F et al. Relationship of circulating sex hormone-binding globulin with metabolic traits in humans. Diabetes 2010; 59: 3167-3173.
4. Bonnet F, Cephise F, Gautier A, Dubois S, Massart C, Camara A et al. Role of sex steroids, intra-hepatic fat and liver enzymes in the association between SHBG and metabolic features. Clin Endocrinol (Oxf) 2013; 79: 517-522
5. Park S, Jeon W, Kim S, Kim H, Park D, Cho Y et al. Prevalence and risk factors of non-alcholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006; 21: 138-143.
6. Volzke H, Schwarz S, Baumeister S, Wallaschofski H, Schwahn C, Grabe H et al. Menopausal status and hepatic steatosis in a general female population. Gut 2007; 56: 594-595.
7. Sowers M, Zheng H, McConnell D, Nan B, Karvonen-Gutierrez C, Randolph J Jr. Testosterone, sex hormone-binding globulin, and free-androgen index among adult women: chronological and ovarian aging. Hum Reprod 2009; 24: 2276-2285.
8. Janssen I, Powell L, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and the metabolic syndrome. Arch Intern Med 2008; 168: 1568-1575.
9. Clark J, Diehl A. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology 2003; 124: 248-250.
10. Wagenknecht L, Scherzinger A, Stamm E, Hanley A, Norris J, Chen Y et al. Correlates and heritability of non-alcoholic fatty liver disease in a minority cohort. Obesity 2009; 17: 1240-1246.
11. Randolph J Jr, Zheng H, Sowers M, Crandall C, Crawford S, Gold E et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab 2011; 96: 746-754.
12. Setiawan V, Pike M, Kolonel L, Nomura A, Goodman M, Henderson B. Racial/ethnic differences in endometrial cancer risk: the Multiethnic Cohort Study. Am J Epidemiol 2006; 165: 262-270.
13. McTiernan A, Wu L, Barnabei V, Chen C, Hendrix S, Modugno F et al. Relation of demographic factors, menstrual history, reproduction and medication use to sex hormone levels in postmenpausal women. Breast Cancer Res 2008; 108: 217-231.
14. Golden S, Dobs A, Vaidya D, Szklo M, Gapstur S, Kopp P et al. Endogenous sex hormones and glucose tolerance status in postmenopausal women. J Clin Endocrinol Metab 2007; 92: 1289-1295.
15. Guerrero R, Vega G, Grundy S, Browning J. Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology 2009; 49: 791-801.
16. North K, Graff M, Franceschini N, Reiner A, Feitosa M, Carr J et al. Sex and race differences in the prevalence of fatty liver disease as measured by computed tomography liver attenuation in European-American and African-American participants of the NHLBI Family Heart Study. Eur J Gastroenterol Hepatol 2012; 24: 9-16.
17. Sowers M, Derby C, Jannausch M, Torrens J, Pasternak R. Insulin resistance, hemostatic factors, and hormone interactions in pre- and perimenopausal women: SWAN. J Clin Endocrinol Metab 2003; 88: 4904-4910.
18. Sutton-Tyrrell K, Wildman R, Matthews K, Chae C, Lasley B, Brockwell S et al. Sex-hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation 2005; 111: 1242-1249.
19. Sowers M, McConnell D, Jannausch M, Randolph J, Brook R, Gold E et al. Oestrogen metabolites in relation to isoprostanes as a measure of oxidative stress. Clin Endocrinol (Oxf) 2008; 68: 806-813.
20. Hanson R, Pratley R, Bogardus C, Narayan K, Roumain J, Imperatore G et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 2000; 151: 190-198.
21. Randolph J Jr, Sowers M, Gold E, Mohr B, Luborsky J, Santoro N et al. Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, a4nd menopausal status. J Clin Endocrinol Metab 2003; 88: 1516-1522.
22. Price JF, Reynolds RM, Mitchell RJ, Williamson RM, Fowkes FG, Deary IJ et al. The Edinburgh Type 2 Diabetes Study: study protocol. BMC Endocr Disord 2008; 8: 18.
23. Williamson R, Price J, Glancy S, Perry E, Nee L, Hayes P et al. Prevalence of and risk factors for hepatic steatosis and non-alcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 2011; 34: 1139-1144.
24. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism, and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012; 55: 885-904.
25. Akaike H. A new look at the Bayes procedure. Biometrika 1978; 65: 53-59.
26. Ma R, Liu K, Lam P, Cheung L, Tam W, Ko G et al. Sonographic measurement of mesenteric fat predicts presence of fatty liver among subjects with polycystic ovary syndrome. J Clin Endocrinol Metab 2011; 96: 799-807.
27. Jones H, Sprung V, Pugh C, Daousi C, Irwin A, Aziz N et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to non-hyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab 2012; 97: 3709-3716.
28. Shin J, Kim S, Lee M, Kim H, Ye B, Shin Y et al. Serum sex hormone-binding globulin levels are independently associated with non-alcoholic fatty liver disease in people with type 2 diabetes. Diabetes Res Clin Pract 2011; 94: 156-162.
29. Browning J, Szczepaniak L, Dobbins R, Nuremberg P, Horton J, Cohen J et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395.
30. Brilakis E, Khera A, McGuire D, See R, Banerjee S, Murphy S et al. Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. Atherosclerosis 2008; 199: 110-115.
31. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio L et al. Genetic variation in PNPLA3 confers susceptibility to non-alcoholic fatty liver disease. Nat Genet 2008; 40: 1461-1465.
32. Speliotes E, Yerges-Armstrong L, Wu J, Hernaez R, Kim L, Palmer C et al. Genome-wide association analysis identifies variants associated with non-alcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7: e1001324.
33. Matafome P, Louro T, Rodrigues L, Crisostomo J, Nunes E, Amaral C et al. Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. Diabetes Metab Res Rev 2011; 27: 54-62.
34. Nestler J. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008; 358: 47-54.